Drug Interactions of Meglitinide Antidiabetics Involving CYP Enzymes and OATP1B1 Transporter

Overview

Journal Ther Adv Endocrinol Metab

Specialty Endocrinology

Date 2018 Sep 6

PMID 30181852

Citations 4

Authors

Naina Mohamed Pakkir Maideen

Gobinath Manavalan

Kumar Balasubramanian

Affiliations

Soon will be listed here.

Abstract

Meglitinides such as repaglinide and nateglinide are useful to treat type 2 diabetes patients who follow a flexible lifestyle. They are short-acting insulin secretagogues and are associated with less risk of hypoglycemia, weight gain and chronic hyperinsulinemia compared with sulfonylureas. Meglitinides are the substrates of cytochrome P450 (CYP) enzymes and organic anion transporting polypeptide 1B1 (OATP1B1 transporter) and the coadministration of the drugs affecting them will result in pharmacokinetic drug interactions. This article focuses on the drug interactions of meglitinides involving CYP enzymes and OATP1B1 transporter. To prevent the risk of hypoglycemic episodes, prescribers and pharmacists must be aware of the adverse drug interactions of meglitinides.

Citing Articles

Polyphenolic Compounds in Fabaceous Plants with Antidiabetic Potential.

Guerrero-Becerra L, Morimoto S, Arrellano-Ordonez E, Morales-Miranda A, Guevara-Gonzalez R, Feregrino-Perez A Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861134 PMC: 11768933. DOI: 10.3390/ph18010069.

Orthogonal Gelations to Synthesize Core-Shell Hydrogels Loaded with Nanoemulsion-Templated Drug Nanoparticles for Versatile Oral Drug Delivery.

Attia L, Chen L, Doyle P Adv Healthc Mater. 2023; 12(31):e2301667.

PMID: 37507108 PMC: 11469203. DOI: 10.1002/adhm.202301667.

An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers.

Maideen N, Balasubramanian R, Muthusamy S, Nallasamy V Curr Cardiol Rev. 2022; 18(6):e110522204611.

PMID: 35546745 PMC: 9893153. DOI: 10.2174/1573403X18666220511152330.

Evaluation of hypoglycemic therapeutics and nutritional supplementation for type 2 diabetes mellitus management: An insight on molecular approaches.

Prasathkumar M, Becky R, Anisha S, Dhrisya C, Sadhasivam S Biotechnol Lett. 2022; 44(2):203-238.

PMID: 35119572 DOI: 10.1007/s10529-022-03232-3.

Antidiabetic Activity of (Black Seeds) and Its Active Constituent (Thymoquinone): A Review of Human and Experimental Animal Studies.

Maideen N Chonnam Med J. 2021; 57(3):169-175.

PMID: 34621636 PMC: 8485088. DOI: 10.4068/cmj.2021.57.3.169.

References

Kajosaari L, Niemi M, Backman J, Neuvonen P . Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin Pharmacol Ther. 2006; 79(3):231-42. DOI: 10.1016/j.clpt.2005.11.002. View

Roustit M, Blondel E, Villier C, Fonrose X, Mallaret M . Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. Ann Pharmacother. 2010; 44(4):764-7. DOI: 10.1345/aph.1M597. View

McDermott E, Powell R . Cyclosporin in the treatment of Churg-Strauss syndrome. Ann Rheum Dis. 1998; 57(4):258-9. PMC: 1752577. DOI: 10.1136/ard.57.4.258a. View

Ruslami R, Aarnoutse R, Alisjahbana B, van der Ven A, van Crevel R . Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med Int Health. 2010; 15(11):1289-99. DOI: 10.1111/j.1365-3156.2010.02625.x. View

Jiang X, Samant S, Lesko L, Schmidt S . Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015; 54(2):147-66. PMC: 5677184. DOI: 10.1007/s40262-014-0230-6. View

Sekhar M, Reddy P . Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits. Mol Cell Biochem. 2012; 364(1-2):159-64. DOI: 10.1007/s11010-011-1214-6. View

Niemi M, Neuvonen M, Juntti-Patinen L, Backman J, Neuvonen P . Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. Clin Pharmacol Ther. 2003; 74(1):25-31. DOI: 10.1016/S0009-9236(03)00089-4. View

Penk A, Pittrow L . Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients. Mycoses. 2000; 42 Suppl 2:97-100. View

Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf N . The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos. 2007; 35(5):779-86. DOI: 10.1124/dmd.106.014407. View

10.

Al-Attas S, Amro S . Candidal colonization, strain diversity, and antifungal susceptibility among adult diabetic patients. Ann Saudi Med. 2010; 30(2):101-8. PMC: 2855059. DOI: 10.4103/0256-4947.60514. View

11.

Tanaka C . Clinical pharmacology of deferasirox. Clin Pharmacokinet. 2014; 53(8):679-94. DOI: 10.1007/s40262-014-0151-4. View

12.

Hussar D . Mechanisms of drug interactions. J Am Pharm Assoc. 1969; 9(5):208-9 passim. DOI: 10.1016/s0003-0465(15)31876-0. View

13.

Matsuda S, Koyasu S . Mechanisms of action of cyclosporine. Immunopharmacology. 2000; 47(2-3):119-25. DOI: 10.1016/s0162-3109(00)00192-2. View

14.

Niemi M, Kajosaari L, Neuvonen M, Backman J, Neuvonen P . The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol. 2004; 57(4):441-7. PMC: 1884466. DOI: 10.1046/j.1365-2125.2003.02027.x. View

15.

Landgraf R . Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging. 2001; 17(5):411-25. DOI: 10.2165/00002512-200017050-00007. View

16.

Kumar B, Padshetty N, Bai K, Rao M . Prevalence of Candida in the oral cavity of diabetic subjects. J Assoc Physicians India. 2005; 53:599-602. View

17.

Taher A, Cappellini M . Update on the use of deferasirox in the management of iron overload. Ther Clin Risk Manag. 2009; 5:857-68. PMC: 2773754. DOI: 10.2147/tcrm.s5497. View

18.

Miller C, Phillips L, Ziemer D, Gallina D, COOK C . Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001; 161(13):1653-9. DOI: 10.1001/archinte.161.13.1653. View

19.

Ansari J . Drug interaction and pharmacist. J Young Pharm. 2010; 2(3):326-31. PMC: 2964764. DOI: 10.4103/0975-1483.66807. View

20.

Kalliokoski A, Backman J, Kurkinen K, Neuvonen P, Niemi M . Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther. 2009; 84(4):488-96. DOI: 10.1038/clpt.2008.74. View